CUE Cue Biopharma
Company Analysis
Latest News
Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 18, 2026
Analyst consensus points to Q2 revenue of $3.00 million and an EPS loss of -$1.69, while the stock currently trades at $34.20, significantly below the average...
Cue Biopharma Downgraded to Hold, Following $1.6 Million CEO Stock Sale
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from buy to hold on Saturday. The action follows the company’s August 14 second-quarter earnings report....
Cue Biopharma second quarter 2026 revenue hits $7.9M as CUE-221 acquisition expenses drive losses
Cue Biopharma reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million year-over-year, driven by milestones from its Boehringer...
🔴 Cue Biopharma is trading 6.73% down in after-hours trading as immediate catalyst remains unclear
Cue Biopharma is trading 6.73% down at $31.90 after closing at $34.20 on August 14, 2026; the immediate catalyst remains unclear. - No confirmed...
🟢 Cue Biopharma is trading 11.33% up today with no confirmed catalyst
Cue Biopharma is trading 11.33% up at $34.60, with the cause unclear. - Gains extended from August 11 through August 13; no verified company-specific...
🟢 Cue Biopharma is trading 5.86% up today with no verified company-specific catalyst
Cue Biopharma is trading 5.86% up at $32.90, with no verified company-specific announcement dated August 14, 2026 identified. - The latest official company...
🟢 Cue Biopharma is trading 6% up today as flat July PPI eased rate-hike concerns
Cue Biopharma is trading 5.95% up at $32.23, likely supported by broader risk-on sentiment after flat July PPI eased rate-hike concerns. - No verified...
🔴 Cue Biopharma is trading 10.47% down today with no clear catalyst
Cue Biopharma is trading at $27.23 (-10.47%) after no verified company-specific announcement was identified for August 13, 2026. • The latest official...
🔴 Cue Biopharma is trading 6.25% down today with no verified company-specific announcement identified
Cue Biopharma is trading 6.25% down at $28.52 after no verified company-specific announcement was identified for August 13, 2026. - The latest official...
🟢 Cue Biopharma is trading 5.84% up today with catalyst unconfirmed
Cue Biopharma is trading at $29.89 (+5.84%), with the catalyst unconfirmed. - No verified company-specific announcement is dated August 12, 2026. - The latest...
🔴 Cue Biopharma is trading 5.77% down today with no verified company-specific catalyst identified
Cue Biopharma is trading 5.77% down at $26.61 after no verified company-specific catalyst was identified for August 12, 2026. - Latest official company news...
🟢 Cue Biopharma is trading 5.17% up in pre-market; no verified company-specific catalyst identified
Cue Biopharma is trading 5.17% up in pre-market at $29.70, with no new verified company-specific announcement identified to explain the move. - It rose 8.20%...
🟢 Cue Biopharma is trading 5.6% up in after-hours trading; catalyst remains unconfirmed
Cue Biopharma is trading at $29.82, up +5.61%, while the catalyst remains unconfirmed. - Gained 8.20% during the August 11 regular session before extending...
🟢 Cue Biopharma is trading 12.34% up today — catalyst unconfirmed
Cue Biopharma is trading 12.34% up at $29.32 after no clear company-specific announcement was identified for August 11, 2026. - Investor-relations page lists...
🔴 Cue Biopharma is trading 5.59% down today; immediate catalyst unclear
Cue Biopharma is trading 5.59% down at $25.61, reversing pre-market strength ahead of the expected August 11 earnings report; the immediate catalyst remains...
🟢 Cue Biopharma is trading 5% up in pre-market ahead of expected August 11 earnings report
Cue Biopharma is trading at $28.48, up +5.01% in pre-market, with investors potentially positioning ahead of the expected August 11 earnings report, where...
Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Cue Biopharma to report a consensus loss of $1.38 per share on revenue of $3.0 million, with the current stock...
🟢 Cue Biopharma rises 5.1% — Biotech Sector Rallies on Argenx-Forte M&A Deal
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is trading higher, with the XBI ETF...
🟢 Cue Biopharma is trading 5.2% up today amid biotech momentum and prior deal optimism
Cue Biopharma is trading 5.2% up today at $27.98, driven by broader biotech sector momentum and lingering optimism from recent corporate developments. • The...
Cue Biopharma Appoints Veteran Life Sciences Executive James Ahlers as New CFO
Cue Biopharma has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. Mr. Ahlers brings extensive financial leadership...